Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785333 | 0.78 | TSHR (0.50) | TSHRHIF1ACYP2C9CYP2C19KDM4E | |
| SCHEMBL3911670 | 0.69 | TSHR (0.41) | TSHRHIF1ACYP2C9CYP2C19KDM4E | |
| SCHEMBL947512 | 0.69 | TSHR (0.50) | TSHRHIF1ACYP2C9CYP2C19KDM4E | |
| SCHEMBL30848757 | 0.69 | TSHR (0.50) | TSHRHIF1ACYP2C9CYP2C19KDM4E | |
| SCHEMBL28757028 | 0.67 | — | — | |
| SCHEMBL258272 | 0.67 | ESR1 (0.54) | TSHRCYP2C9CYP2C19CYP3A4ADRA2A | |
| SCHEMBL258651 | 0.67 | TSHR (0.39) | TSHRHIF1ACYP2C9CYP2C19KDM4E | |
| SCHEMBL28548155 | 0.67 | TSHR (0.39) | TSHRHIF1ACYP2C9CYP2C19KDM4E | |
| SCHEMBL2104519 | 0.67 | TSHR (0.39) | TSHRHIF1ACYP2C9CYP2C19KDM4E | |
| SCHEMBL9194828 | 0.67 | TSHR (0.39) | TSHRHIF1ACYP2C9CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1604964-B1 | ZERO-VALENCE TRANSITION METAL COMPLEX AND METHOD OF SYNTHESIZING ORGANOMETALLIC COMPOUND FROM THE SAME AS STARTING MATERIAL | SEKISUI CHEMICAL CO LTD (JP) | 2009-06-10 | — | — | EP | disclosed |
| EP-1431302-B1 | PROCESS FOR SYNTHESIS OF ORGANOMETALLIC COMPOUNDS | SEKISUI CHEMICAL CO LTD (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-7361776-B2 | Zero-valent transition metal complex and method for producing an organometallic compound using the same as a starting material | SEKISUI CHEMICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-7098355-B2 | Process for synthesis of organometallic compounds | SEKISUI CHEMICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20060149088-A1 | Zero-valence transition metal complex and method of synthesizing organometallic compound from the same as starting material | SEKISUI CHEMICAL CO., LTD. (JP) | 2006-07-06 | — | — | US | disclosed |
| US-20060030723-A1 | Process for synthesis of organometallic compounds | SEKISUI CHEMICAL CO., LTD. (JP) | 2006-02-09 | — | — | US | disclosed |
| EP-1604964-A1 | ZERO-VALENCE TRANSITION METAL COMPLEX AND METHOD OF SYNTHESIZING ORGANOMETALLIC COMPOUND FROM THE SAME AS STARTING MATERIAL | SEKISUI CHEMICAL CO., LTD. (JP) | 2005-12-14 | — | — | EP | disclosed |
| EP-1431302-A1 | PROCESS FOR SYNTHESIS OF ORGANOMETALLIC COMPOUNDS | SEKISUI CHEMICAL CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030723-A1 | Process for synthesis of organometallic compounds | CYP4F12, CYP4F2, CYP4F11 | TSHR 3234/4885HIF1A 4436/4885CYP2C9 224/4885 |
| US-20060149088-A1 | Zero-valence transition metal complex and method of synthesizing organometallic compound from the same as starting material | OSTC, PORCN, SQLE | TSHR 4126/4885HIF1A 3371/4885CYP2C9 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.